Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Return on Equity (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Return on Equity readings, the most recent being 0.0% for Q4 2025.

  • Quarterly Return on Equity changed 0.0% to 0.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.0% through Dec 2025, changed 0.0% year-over-year, with the annual reading at 0.0% for FY2025, 1.0% up from the prior year.
  • Return on Equity hit 0.0% in Q4 2025 for Oramed Pharmaceuticals, up from 0.0% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.0% in Q4 2025 and bottomed at 0.0% in Q2 2022.
  • Average Return on Equity over 5 years is 0.0%, with a median of 0.0% recorded in 2021.
  • Peak annual rise in Return on Equity hit 0bps in 2021, while the deepest fall reached 0bps in 2021.
  • Oramed Pharmaceuticals' Return on Equity stood at 0.0% in 2021, then tumbled by -73bps to 0.0% in 2022, then soared by 108bps to 0.0% in 2023, then crashed by -664bps to 0.0% in 2024, then skyrocketed by 381bps to 0.0% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Return on Equity are 0.0% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025).